[1] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016, 66(1): 7-30.
|
[2] |
Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma[J]. Gastroenterology, 2016, 150(4): 835-853.
|
[3] |
Coulon S, Heindryckx F, Geerts A, et al. Angiogenesis in chronic liver disease and its complications[J]. Liver Int, 2011, 31(2): 146-162.
|
[4] |
Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma[J]. N Engl J Med, 2007, 356(2): 125-134.
|
[5] |
Bupathi M, Kaseb A, Janku F. Angiopoietin 2 as a therapeutic target in hepatocellular carcinoma treatment: current perspectives[J]. Onco Targets Ther, 2014(7): 1927-1932.
|
[6] |
Yim KL, Cunningham D. Targeted drug therapies and cancer[J]. Recent Results Cancer Res, 2011(185): 159-171.
|
[7] |
Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma[J]. Drugs, 2009, 69(2): 223-240.
|
[8] |
Li J, Wang L, Cong N, et al. Efficacy of sorafenib for advanced hepatocellular carcinoma and prognostic factors[J]. Hepatogastroenterology, 2014, 61(132): 954-957.
|
[9] |
Mazzocca A, Dituri F, Lupo L, et al. Tumor-secreted lysophostatidic acid accelerates hepatocellular carcinoma progression by promoting differentiation of peritumoral fibroblasts in myofibroblasts[J]. Hepatology, 2011, 54(3): 920-930.
|
[10] |
陈之巨,林楠,潘楚芝,等.活化态肝星状细胞对小鼠肝细胞肝癌血管形成、肿瘤生长及转移的作用[J/CD].中华肝脏外科手术学电子杂志,2013,2(3): 186-193.
|
[11] |
Lin ZY, Chuang YH, Chuang WL. Cancer-associated fibroblasts up-regulate CCL2, CCL26, IL6 and LOXL2 genes related to promotion of cancer progression in hepatocellular carcinoma cells[J]. Biomed Pharmacother, 2012, 66(7): 525-529.
|
[12] |
Jo M, Nishikawa T, Nakajima T, et al. Oxidative stress is closely associated with tumor angiogenesis of hepatocellular carcinoma[J]. J Gastroenterol, 2011, 46(6): 809-821.
|
[13] |
Xing F, Saidou J, Watabe K. Cancer associated fibroblasts (CAFs) in tumor microenvironment[J]. Front Biosci, 2010(15): 166-179.
|
[14] |
Mishra P, Banerjee D, Ben-Baruch A. Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy[J]. J Leukoc Biol, 2011, 89(1): 31-39.
|
[15] |
Yang JD, Nakamura I, Roberts LR. The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets[J]. Semin Cancer Biol, 2011, 21(1): 35-43.
|
[16] |
Yang X, Lin Y, Shi Y, et al. FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling[J]. Cancer Res, 2016, 76(14): 4124-4135.
|
[17] |
Sukowati CH, Anfuso B, Crocé LS, et al. The role of multipotent cancer associated fibroblasts in hepatocarcinogenesis[J]. BMC Cancer, 2015(15): 188.
|
[18] |
Zhu B, Lin N, Zhang M, et al. Activated hepatic stellate cells promote angiogenesis via interleukin-8 in hepatocellular carcinoma[J]. J Transl Med, 2015(13): 365.
|
[19] |
Cong WM, Bu H, Chen J, et al. Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update[J]. World J Gastroenterol, 2016, 22(42): 9279-9287.
|
[20] |
Liccioni A, Reig M, Bruix J. Treatment of hepatocellular carcinoma[J]. Dig Dis, 2014, 32(5): 554-563.
|